NCT06594562 Free Fluid Detection With Telementored eFAST
| NCT ID | NCT06594562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Hemoperitoneum |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-06-18 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-06-18 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This feasibility study will evaluate the accuracy of telementored eFAST (Extended Focused Assessment with Sonography in Trauma) in detecting abdominal free fluid in patients who have recently undergone liver surgery. The primary goal is to determine how well the remote-guided ultrasound can identify fluid accumulation compared to conventional ultrasound performed by a radiologist. Participants in this study will be examined with ultrasound, supported in real-time by a remote expert, to assess its accuracy and other relevant performance metrics.
Eligibility Criteria
Inclusion Criteria: Patients who have undergone laparoscopic liver surgery at the Oslo university hospital and are within 72 post-surgery Exclusion Criteria: Allergy to ultrasound gel. Patients colonized with ESBL, MRSA and VRE will be excluded due to infection control. Significant postoperative pain that can exacerbated by probe pressure.
Contact & Investigator
Henrik Brun, Professor
STUDY DIRECTOR
Oslo University Hospital
Frequently Asked Questions
Who can join the NCT06594562 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemoperitoneum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06594562 currently recruiting?
Yes, NCT06594562 is actively recruiting participants. Contact the research team at peder_engelsen@hotmail.com for enrollment information.
Where is the NCT06594562 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT06594562 clinical trial?
NCT06594562 is sponsored by Oslo University Hospital. The principal investigator is Henrik Brun, Professor at Oslo University Hospital. The trial plans to enroll 40 participants.